Verve Therapeutics, Inc. (VERV) Tops Q4 EPS by 14c

Verve Therapeutics, Inc. (NASDAQ: VERV) reported Q4 EPS of ($0.69), $0.14 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $5.14 million versus the consensus estimate of $1.17 million.

For earnings history and earnings-related data on Verve Therapeutics, Inc. (VERV) click here.

You May Also Be Interested In

• SanDisk stock target lifted at Bernstein to $3000 on new memory LTAs
• Chip stocks hit record 19.7% of S&P 500, quadrupling since 2020
• Piper Sandler picks Payments and Consumer Finance winners as multiples reset